Iria Pharma, a spin-off from the University of Illinois, is focused on developing a novel drug delivery technology called Active Tissue Targeting via Anchored ClicK Chemistry (ATTACK) for cancer treatment. This technology involves labeling cancer cells with azido-sugar and then delivering a targeted therapeutic agent through a specific chemical reaction. The company is currently seeking commercial partners and strategic collaborators for further research and development. Founded in 2016 and based in Champaign, Illinois, Iria Pharma aims to provide a platform for targeted cancer therapeutics.